Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.996 CHF
−67.97 M CHF
49.21 M CHF
134.99 M
About Ocular Therapeutix, Inc.
Sector
CEO
Pravin U. Dugel
Headquarters
Bedford
Website
Founded
2006
FIGI
BBG00LVF1G44
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
OCUL - long - upcoming catalystOcular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation
OCUL LongAnother chance for a clean swing at nearly 2 r/r. Looks like a complex pullback, but pullback it is.
$OCUL Ocular Therapeutix Inc Long term Target PT 29 and higherNASDAQ:OCUL Ocular Therapeutix Inc
Long term Target PT 29 and higher
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technolo
OCUL is looking attractive OCUL is shaping up for a good risk reward set up.
$3.60 before resistance and well within major downtrend line.
Starter position below $3.
Will add if it falls closer to $2.50, where it has lots of support.
Profit opportunity is 10 - 20%
OCUL good swing opportunity available if price retestsOCUL created a pro gap and if price comes to retest , planning to take a long swing poistion to fill the sep 22 gap .
oculari have no idea what this is but the 50ema is about to coincide with the midpoint of bb, and td89 just happened, so i bet it bounces
$OCUL PT 40 and higherCup and Handle formation
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic d
OCUL. More Chaos than Order.This is a great example of a chart that makes me realize there is much more to learn. I know there is a way to classify almost every market, but for the life of me I don't know this one.
That makes me all the more motivated to monitor it, however.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0OT is 8.776 CHF — it has increased by 15.19% in the past 24 hours. Watch OCULAR THERAPEUTIX stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange OCULAR THERAPEUTIX stocks are traded under the ticker 0OT.
0OT stock hasn't changed in a week, the month change is a 15.19% rise, over the last year OCULAR THERAPEUTIX has showed a 15.19% increase.
We've gathered analysts' opinions on OCULAR THERAPEUTIX future price: according to them, 0OT price has a max estimate of 19.04 CHF and a min estimate of 9.52 CHF. Watch 0OT chart and read a more detailed OCULAR THERAPEUTIX stock forecast: see what analysts think of OCULAR THERAPEUTIX and suggest that you do with its stocks.
0OT stock is 13.18% volatile and has beta coefficient of 2.08. Track OCULAR THERAPEUTIX stock price on the chart and check out the list of the most volatile stocks — is OCULAR THERAPEUTIX there?
Today OCULAR THERAPEUTIX has the market capitalization of 1.46 B, it has decreased by −8.15% over the last week.
Yes, you can track OCULAR THERAPEUTIX financials in yearly and quarterly reports right on TradingView.
OCULAR THERAPEUTIX is going to release the next earnings report on Nov 14, 2024. Keep track of upcoming events with our Earnings Calendar.
0OT earnings for the last quarter are −0.23 CHF per share, whereas the estimation was −0.20 CHF resulting in a −17.51% surprise. The estimated earnings for the next quarter are −0.21 CHF per share. See more details about OCULAR THERAPEUTIX earnings.
OCULAR THERAPEUTIX revenue for the last quarter amounts to 14.78 M CHF, despite the estimated figure of 14.25 M CHF. In the next quarter, revenue is expected to reach 14.51 M CHF.
0OT net income for the last quarter is −39.36 M CHF, while the quarter before that showed −58.50 M CHF of net income which accounts for 32.72% change. Track more OCULAR THERAPEUTIX financial stats to get the full picture.
No, 0OT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 267.00 employees. See our rating of the largest employees — is OCULAR THERAPEUTIX on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OCULAR THERAPEUTIX EBITDA is −99.56 M CHF, and current EBITDA margin is −135.86%. See more stats in OCULAR THERAPEUTIX financial statements.
Like other stocks, 0OT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OCULAR THERAPEUTIX stock right from TradingView charts — choose your broker and connect to your account.